Product
Domatinostat
1 clinical trial
1 indication
Indication
Malignant Melanoma Stage IIIClinical trial
Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary MelanomaStatus: Active (not recruiting), Estimated PCD: 2022-01-11